3-Phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Akt-independent manner

Neoplasia (United States)

Volumn 14, Issue 8, 2012, Pages 719-731

  Gagliardi, Paolo Armando ^a,b   di Blasio, Laura ^a,b   Orso, Francesca ^b,c,d   Seano, Giorgio ^a,b   Sessa, Roberto ^a,b   Taverna, Daniela ^b,c,d   Bussolino, Federico ^a,b,d   Primo, Luca ^a,d,e  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Molecular Biotechnology Center   (Italy)

^d Center for Complex Systems in Molecular Biology and Medicine   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RETROVIRUS VECTOR;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL TISSUE; ANOIKIS; APOPTOSIS; ARTICLE; BREAST CANCER; CLONING; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; KRAS GENE; MOUSE; NONHUMAN; PIK3CA GENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84865202387     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12856     Document Type: Article

References (50)

1. Baselga J (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist 16(suppl 1), 12-19.
2. Vivanco I and Sawyers CL (2002). The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2, 489-501.
3. Cantley LC (2002). The phosphoinositide 3-kinase pathway. Science 296, 1655-1657.
4. Pearce LR, Komander D, and Alessi DR (2010). The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 11, 9-22.
5. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, and Cohen P (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr Biol 7, 261-269.
6. Currie RA, Walker KS, Gray A, Deak M, Casamayor A, Downes CP, Cohen P, Alessi DR, and Lucocq J (1999). Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J 337(pt 3), 575-583.
7. s6k by PDK1. Science 279, 707-710.
8. Kobayashi T and Cohen P (1999). Activation of serum- and glucocorticoid-regulated protein kinase by agonists that activate phosphatidylinositide 3-kinase is mediated by 3-phosphoinositide-dependent protein kinase-1 (PDK1) and PDK2. Biochem J 339(pt 2), 319-328.
9. Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, and Frodin M (1999). 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1. J Biol Chem 274, 27168-27176.
10. Le Good JA, Ziegler WH, Parekh DB, Alessi DR, Cohen P, and Parker PJ (1998). Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281, 2042-2045.
11. Biondi RM, Kieloch A, Currie RA, Deak M, and Alessi DR (2001). The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 20, 4380-4390.
12. Tian X, Rusanescu G, Hou W, Schaffhausen B, and Feig LA (2002). PDK1 mediates growth factor-induced Ral-GEF activation by a kinase-independent mechanism. EMBO J 21, 1327-1338.
13. Pinner S and Sahai E (2008). PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol 10, 127-137.
14. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68, 6084-6091.
15. Wu G, Xing M, Mambo E, Huang X, Liu J, Guo Z, Chatterjee A, Goldenberg D, Gollin SM, Sukumar S, et al. (2005). Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 7, R609-R616.
16. Carvalho S, Milanezi F, Costa JL, Amendoeira I, and Schmitt F (2010). PIKing the right isoform: the emergent role of the p110β subunit in breast cancer. Virchows Arch 456, 235-243.
17. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, et al. (2001). AKT1/PKBα kinase is frequently elevated in human cancers and its constitutive activation is required for onco-genic transformation in NIH3T3 cells. Am J Pathol 159, 431-437.
18. Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, and Testa JR (2002). AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival. Oncogene 21, 3532-3540.
19. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, et al. (2009). 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 69, 6299-6306.
20. van der Hage JA, van den Broek LJ, Legrand C, Clahsen PC, Bosch CJ, Robanus-Maandag EC, van de Velde CJ, and van de Vijver MJ (2004). Overexpression of p70 S6 kinase protein is associated with increased risk of locoregional recurrence in node-negative premenopausal early breast cancer patients. Br J Cancer 90, 1543-1550.
21. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, et al. (2007). Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079.
22. Xie Z, Yuan H, Yin Y, Zeng X, Bai R, and Glazer RI (2006). 3-Phosphoinositide- dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 6, 77.
23. Lin HJ, Hsieh FC, Song H, and Lin J (2005). Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer 93, 1372-1381.
24. Xie Z, Zeng X, Waldman T, and Glazer RI (2003). Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 activates β-catenin and c-Myc, and down-regulates caveolin-1. Cancer Res 63, 5370-5375.
25. Zeng X, Xu H, and Glazer RI (2002). Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Ca. Cancer Res 62, 3538-3543.
26. Nagashima K, Shumway SD, Sathyanarayanan S, Chen AH, Dolinski B, Xu Y, Keilhack H, Nguyen T, Wiznerowicz M, Li L, et al. (2011). Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem 286, 6433-6448.
27. Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB, and Fan Z (2006). Differential roles of phosphoinositide-dependent protein kinase-1 and Akt1 expression and phosphorylation in breast cancer cell resistance to paclitaxel, doxorubicin, and gemcitabine. Mol Pharmacol 70, 1045-1052.
28. Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, and Pollak M (2006). Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 70, 1534-1541.
29. Iorns E, Lord CJ, and Ashworth A (2009). Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J 417, 361-370.
30. Tan J, Lee PL, Li Z, Jiang X, Lim YC, Hooi SC, and Yu Q (2010). B55β-associated PP2A complex controls PDK1-directed Myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 18, 459-471.
31. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A, Olshen AB, Gerald WL, and Massague J (2005). Genes that mediate breast cancer metastasis to lung. Nature 436, 518-524.
32. Primo L, di Blasio L, Roca C, Droetto S, Piva R, Schaffhausen B, and Bussolino F (2007). Essential role of PDK1 in regulating endothelial cell migration.J Cell Biol 176, 1035-1047.
33. Follenzi A, Ailles LE, Bakovic S, Geuna M, and Naldini L (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25, 217-222.
34. Primo L, Roca C, Ferrandi C, Lanfrancone L, and Bussolino F (2000). Human endothelial cells expressing polyoma middle T induce tumors. Oncogene 19, 3632-3641.
35. Casamayor A, Morrice NA, and Alessi DR (1999). Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo. Biochem J 342(pt 2), 287-292.
36. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, et al. (2005). Colorectal cancer: mutations in a signalling pathway. Nature 436, 792.
37. Bayascas JR, Leslie NR, Parsons R, Fleming S, and Alessi DR (2005). Hypo-morphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol 15, 1839-1846.
38. Finlay DK, Sinclair LV, Feijoo C, Waugh CM, Hagenbeek TJ, Spits H, and Cantrell DA (2009). Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes. J Exp Med 206, 2441-2454.
39. Mora A, Komander D, van Aalten DM, and Alessi DR (2004). PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 15, 161-170.
40. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, et al. (2009). AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16, 21-32.
41. Raimondi C, Chikh A, Wheeler AP, Maffucci T, and Falasca M (2012). A novel regulatory mechanism links PLCy1 to PDK1. J Cell Sci, E-pub ahead of print May 18.
42. Biondi RM, Cheung PC, Casamayor A, Deak M, Currie RA, and Alessi DR (2000). Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J 19, 979-988.
43. McManus EJ, Collins BJ, Ashby PR, Prescott AR, Murray-Tait V, Armit LJ, Arthur JS, and Alessi DR (2004). The in vivo role of PtdIns(3,4,5)P3 binding to PDK1 PH domain defined by knockin mutation. EMBO J 23, 2071-2082.
44. Lawlor MA, Mora A, Ashby PR, Williams MR, Murray-Tait V, Malone L, Prescott AR, Lucocq JM, and Alessi DR (2002). Essential role of PDK1 in regulating cell size and development in mice. EMBO J 21, 3728-3738.
45. Ellwood-Yen K, Keilhack H, Kunii K, Dolinski B, Connor Y, Hu K, Nagashima K, O'Hare E, Erkul Y, Di Bacco A, et al. (2011). PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res 71, 3052-3065.
46. Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu D, Biroc SL, Alicke B, Bryant J, Yuan S, et al. (2005). Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 280, 19867-19874.
47. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, and Ogier-Denis E (2002). Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277, 27613-27621.
48. Najafov A, Sommer EM, Axten JM, Deyoung MP, and Alessi DR (2011). Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J 433, 357-369.
49. Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BV, Broggini M, and Maffucci T (2010). A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer 102, 104-114.
50. Medina JR, Becker CJ, Blackledge CW, Duquenne C, Feng Y, Grant SW, Heerding D, Li WH, Miller WH, Romeril SP, et al. (2011). Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. J Med Chem 54, 1871-1895.